Imatinib induced melasma-like pigmentation
Abstract
Imatinib mesylate, a tyrosine kinase inhibitor, is used for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST), mastocytosis, myelodysplastic and myeloproliferative disorders. Cutaneous side effects of imatinib include xerosis, photosensitivity, pigmentary changes hypopigmentation and rarely hyperpigmentation. A 19-years-old male diagnosed case of CML currently on Imatinib 400mg once daily for 18 months presented with gradually progressive brownish discoloration of face since 6 months. Based on history, clinical features and a temporal association with drug intake, a diagnosis of imatinib-induced melasma-like pigmentation was made and the patient was started on sunscreen and topical depigmenting agents.ÂReferences
Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma - like pigmentation: Report of five cases and review of literature. Indian J Dermatol Venereol Leprol 2016; 82: 409-12.
Balasubramanian P, Jagadeesan S, Thomas J. Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia. Indian J Dermatol 2015; 60: 523.
Balagula Y, Pulitzer MP, Maki RG, Myskowski PL. Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol. 2011; 10: 10626.
Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistant cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 2008; 14: 7.
Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: Report of three cases. Head Neck Pathol 2012; 6: 290-5.
